CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes Angiotensin–neprilysin inhibition versus enalapril in heart failure Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Sex- and Race-Related Differences in Characteristics and Outcomes of Hospitalizations for Heart Failure With Preserved Ejection Fraction Clinical epidemiology of heart failure with preserved ejection fraction (HFpEF) in comparatively young hospitalized patients

Clinical Trial15 Nov 2021

JOURNAL:Circulation. Article Link

Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial

J Butler, G Filippatos, TJ Siddiqi et al. Keywords: HFpEF; empagliflozin; health status

Full Text PDF